‘It’s Happened Before:’ Biz Leaders React to Biogen Idec’s San Diego Shutdown

11/4/10Follow @bvbigelow

[Corrected 11/04/10, 9:25 am to reflect merger] When Cambridge, MA-based Biogen consummated its merger with San Diego’s Idec Pharmaceuticals in November 2003, Executive Chairman William H. Rastetter said, “Based on our existing collaboration in oncology, we knew that this combination would be an excellent fit, both operationally and culturally,” according to a statement issued at the time.

Now, just seven years after closing the $6.8 billion deal, Biogen Idec said yesterday it plans to shut down its San Diego research and corporate campus, which focused on cancer drug development, and lay off most of its San Diego employees. Rastetter, who was Idec Pharmaceutical’s founding CEO (and who joined Venrock’s Palo Alto, CA, office in 2006), declined to comment yesterday.

Other local business leaders said the shutdown is both a sign of the times, and a pattern that has become all-too-familiar among the venture-backed companies that often shut down or depart San Diego’s “grow to sell” market.

“I can fully understand why they decided to do it,” said Julie Meier Wright, CEO of the San Diego Regional Economic Development Corp. “It reminds me of some other corporate decisions we’ve seen here, like Gateway, General Dynamics, and even Hughes Aerospace, years ago.” Biogen Idec, she added, is “a first-rate company, and ideally their people will be absorbed here in San Diego.”

Biocom CEO Joe Panetta sounded a similar theme when I caught up with him yesterday during an all-day conference the local life sciences industry group had organized to focus on human resources training.

“From a historical standpoint, it’s sad to see that one of the original biotech companies in San Diego is now closing its doors here,” Panetta said. But he also noted that a recurring theme of the HR conference was the challenge to find experienced and highly talented employees in the life sciences. “It’s unfortunate, but it’s the story of the biotech industry in San Diego,” Panetta said. It’s happened before, and I can point you to any number of people who were laid off and went on to start great biotech companies.”

Panetta added, “This closure to me is not indicative of … Next Page »

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

Single Page Currently on Page: 1 2

By posting a comment, you agree to our terms and conditions.

  • Plodna

    Idec Pharmaceuticals bought Biogen – not the other way around. Genentech sued arguing that there had been a change in control of the company to get ownership of Rituxan but Biogen Idec successfully argued in court that it was still Idec Pharmaceuticals with only a name change to reflect the merger. The balance of power has clearly been the reverse though.

  • http://www.xconomy.com/author/bbigelow/ Bruce V. Bigelow

    Thanks for this.

  • http://www.johnconner.com John

    It’s a shame they didn’t offer a transfer. Most probably wouldn’t move away from S.D. but an offer would have been much better considering media relations.

  • Else

    About a quarter of the affected employees have been offered relocation packages.

  • June

    No surprise – our continuing business unfriendly environment, high taxes, over regulation and high real estate costs for both employers and employees are a constant discouragement for expansion.

    I suspect with the incoming Ca. state leadership we will see companies fleeing the state – lured away by more business friendly, affordable cities that welcome corporate growth and reward hiring.